[go: up one dir, main page]

WO1996032403A3 - Neue cytosin- und cytidinderivate - Google Patents

Neue cytosin- und cytidinderivate Download PDF

Info

Publication number
WO1996032403A3
WO1996032403A3 PCT/EP1996/001595 EP9601595W WO9632403A3 WO 1996032403 A3 WO1996032403 A3 WO 1996032403A3 EP 9601595 W EP9601595 W EP 9601595W WO 9632403 A3 WO9632403 A3 WO 9632403A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytidine derivatives
cytosine
novel
novel cytosine
cytidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/001595
Other languages
English (en)
French (fr)
Other versions
WO1996032403A2 (de
Inventor
Helmut Vorbrueggen
Konrad Krolikiewicz
Michael Schirner
Martin Schneider
Herbert Wiesinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to AU54000/96A priority Critical patent/AU5400096A/en
Publication of WO1996032403A2 publication Critical patent/WO1996032403A2/de
Publication of WO1996032403A3 publication Critical patent/WO1996032403A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Cytosin- und Cytidin-Derivate der allgemeinen Formel (1), sowie deren Herstellung und Verwendung in Arzneimitteln.
PCT/EP1996/001595 1995-04-12 1996-04-12 Neue cytosin- und cytidinderivate Ceased WO1996032403A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54000/96A AU5400096A (en) 1995-04-12 1996-04-12 Novel cytosine and cytidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19514523.2 1995-04-12
DE1995114523 DE19514523A1 (de) 1995-04-12 1995-04-12 Neue Cytosin- und Cytidinderivate

Publications (2)

Publication Number Publication Date
WO1996032403A2 WO1996032403A2 (de) 1996-10-17
WO1996032403A3 true WO1996032403A3 (de) 1996-11-28

Family

ID=7759937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/001595 Ceased WO1996032403A2 (de) 1995-04-12 1996-04-12 Neue cytosin- und cytidinderivate

Country Status (3)

Country Link
AU (1) AU5400096A (de)
DE (1) DE19514523A1 (de)
WO (1) WO1996032403A2 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP3109244B1 (de) 2004-09-14 2019-03-06 Gilead Pharmasset LLC Herstellung von 2'fluor-2'-alkyl-substituierten oder von anderen wahlweise substituierten ribofuranosylpyrimidinen und -purinen und deren derivaten
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EA026341B9 (ru) 2010-03-31 2021-12-27 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Кристаллическая форма нуклеозидфосфорамидата
UA118256C2 (uk) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Комбінований склад двох противірусних сполук
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62255499A (ja) * 1986-04-28 1987-11-07 Teijin Ltd 螢光性ヌクレオシド又はヌクレオチド
WO1991011186A1 (en) * 1990-02-01 1991-08-08 Emory University Method and compositions for the synthesis of bch-189 and related compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62255499A (ja) * 1986-04-28 1987-11-07 Teijin Ltd 螢光性ヌクレオシド又はヌクレオチド
WO1991011186A1 (en) * 1990-02-01 1991-08-08 Emory University Method and compositions for the synthesis of bch-189 and related compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRODFUEHRER P.R. ET AL: "A Practical Synthesis of (S)-HPMPC", TETRAHEDRON LETTERS, vol. 35, no. 20, 1994, OXFORD GB, pages 3243 - 3246, XP002012084 *
ELEVENTH INTERNATIONAL ROUND TABLE ON NUCLEOSIDES, NUCLEOTIDES AND THEIR BIOLOGICAL APPLICATIONS, 7 September 1994 (1994-09-07) - 11 September 1994 (1994-09-11), LEUVEN, BE *
HARNDEN M.R. ET AL: "Novel Acyclonucleotides: Synthesis and Antiviral Activity of Alkenylphosponic Acid Derivatives of Purines and a Pyrimidine", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, 1993, WASHINGTON US, pages 1343 - 1355, XP002012083 *
LOAKES, D. ET AL: "The synthesis of bicyclic N4-amino-2'-deoxycytidine derivatives", NUCLEOSIDES NUCLEOTIDES, vol. 14, no. 3-5, May 1995 (1995-05-01), pages 291 - 293, XP002013445 *
PATENT ABSTRACTS OF JAPAN vol. 012, no. 139 (C - 491) 27 April 1988 (1988-04-27) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9394331B2 (en) 2010-11-30 2016-07-19 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Also Published As

Publication number Publication date
DE19514523A1 (de) 1996-10-17
WO1996032403A2 (de) 1996-10-17
AU5400096A (en) 1996-10-30

Similar Documents

Publication Publication Date Title
AU7693396A (en) Poly(9,9'-spiro-bisfluorenes), the production and use of same
AU1231492A (en) Substituted phenyl-1,3 dioxoloquinoline derivatives and their use as antitumor agents
IL119488A (en) Substituted 2, 4-imidazolidinediones, their production and pharmaceutical compositions containing them
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
CA2219818A1 (en) Novel compounds, the preparation and use thereof
PL380081A1 (pl) Pochodne 3,3-difenylopropyloamin, sposoby ich wytwarzania, kompozycja farmaceutyczna oraz zastosowania
HUP9900881A3 (en) 4,5-diaryl oxazole derivatives and pharmaceutical compositions containing them
HUP0004225A3 (en) Pyridine derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
HUP9903707A3 (en) Lactone derivatives of 17.beta.-carboxy,carbothio and amide androstane derivatives, their production, use thereof and medicament containing them
AU3284395A (en) Synthesis of 1,1,1,3,3,-pentafluoropropane
WO1996032403A3 (de) Neue cytosin- und cytidinderivate
IL122987A0 (en) Novel 2,3-dioso-1, 2, 3, 4-tetrahydro-quinoxalinyl derivatives
AU4329396A (en) Use of 3,4-diphenylchromans
AU6636598A (en) Novel 3,4-dialkoxyphenyl derivatives and the use thereof
HUP9801356A3 (en) Triciclic (2-hydroxy-2-methyl-3,3,3-trifluoropropanoyl)-amino-benzoxepine, -benzothiepine, -benzocycloheptene, -indene derivatives and pharmaceutical compositions containing them
HUP9802807A3 (en) 1,3,8-triazo-spiro[4,5]decan-4-on derivatives, their use, production thereof and medicaments containing the same
AU640820B2 (en) 1,3-benzoxazine derivatives, their production and use
ZA967920B (en) Production and use of isolated type 5 17beta-hydroxysteroid dehydrogenase.
PL340372A1 (en) Novel 3,6x-hemiketals of 9a-azalydes class
AU7978794A (en) 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
HUP0102025A3 (en) Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
HUP9900924A3 (en) Substituted 1 betha-d-arabinofuranosylcytosine derivatives and use of the same for producing pharmaceutical compositions having antitumor activity
NO960699L (no) Antimigren 1,2,5-tiadiazolderivater av indolylalkylpyridinyl- og -pyrimidinylpiperaziner
AU3467697A (en) 3'-oximino-2',3'-dideoxynucleosides and derivatives of the same
HUP9801068A2 (hu) 1,2,3,4-Tetrahidro-2-naftil-amin-származékok, ezek előállítása és alkalmazása, valamint ilyen származékokat tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA